Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice

Antisense and Nucleic Acid Drug Development

Volumn 10, Issue 5, 2000, Pages 359-368

  Templin, M V ^a   Levin, A A ^a   Graham, M J ^a   Aberg, P M ^a   Axelsson, B I ^b   Butler, M ^a   Geary, R S ^a   Bennett, C F ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AFOVIRSEN; ANTISENSE OLIGONUCLEOTIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

AEROSOL; ANIMAL TISSUE; ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; LUNG ALVEOLUS EPITHELIUM; LUNG ENDOTHELIUM; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING;

ANIMALIA;

EID: 0033763150     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.2000.10.359     Document Type: Article

References (29)

1. Pharmacokinetics of antisense oligonucleotides
2. 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells
3. Oligonucleotide-based inhibitors of cytokine expression and function
4. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues
5. The flow-past chamber: An improved nose-only exposure system for rodents
6. 14C-labeled phosphorothioate oligonucleotide. ISIS 2105, after intravenous administration to rats
7. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats
8. Antisense therapies
9. The use of complementary/alternative medicine for the treatment of asthma in the United States
10. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of c-raf-1 kinase expression
11. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides
12. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice
13. Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats
14. Clinical antiviral activities
15. Role of the intracellular adhesion molecule (ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice
16. Quantitation of phosphorothioate oligonucleotides in human plasma
17. Toxicity of oligodeoxynucleotide therapeutic agents
18. Species differences in aerosol deposition
19. Production and characterization of aerosols
20. A multi-stage low flow rate cascade impactor
21. First 'antisense' drug will treat CMV retinitis
22. Why is asthma becoming more of a problem?
23. Immune stimulation - A class effect of phosphorothioate oligodeoxynucleotides in rodents
24. Pulmonary bioavailability of a phosphorothioate oligodeoxynucleotide (CGP 64128A): Comparison with other delivery routes
25. DNA antisense therapy for asthma in an animal model
26. Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice
27. In vivo toxicologic effects of a rel A antisense phosphorothioates in CD-1 mice
28. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease